Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986507 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986507 | DRUG | Specified dose on specified days |
| Osimertinib | DRUG | Specified dose on specified days |
| Pembrolizumab | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have at least one measurable lesion per response evaluation criteria in solid tumors. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have a life expectancy of at least 3 months at the tim...
Top 20 of 76 competitors
BMS-986507 is an investigational small molecule being developed for the treatment of lung cancer. It is currently being studied in a Phase 1 clinical trial in adult participants with advanced solid tumors, including lung cancer and breast cancer. The drug is not yet approved and is still in clinical development.
BMS-986507 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a Phase 1 clinical trial to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 in combination with other treatments.
BMS-986507 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants and is designed to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adults with advanced solid tumors.
BMS-986507 is being studied in a Phase 1 clinical trial with the identifier NCT06618287. This trial is recruiting 416 participants and is evaluating BMS-986507 combinations in adult participants with advanced solid tumors, including lung cancer and breast cancer. The trial is being conducted in multiple countries, including the United States, Australia, Canada, and several European countries.
Yes, the Phase 1 clinical trial of BMS-986507 is randomized and controlled. The trial is not double-blinded, but it includes a control group. The study is actively recruiting participants with advanced solid tumors, including lung cancer and breast cancer, and is being conducted at sites in the United States, Australia, Canada, Chile, France, Italy, Netherlands, Spain, Taiwan, and the United Kingdom.